Biogen makes changes to R&D department on eve on FDA lecanemab decision
Sean Anthony Eddy


Biogen (NASDAQ:BIIB) is separating its research and development department into two separate units, a day before the US FDA is set to act on its application for Alzheimer's therapy lecanemab.
Priya Singhal, currently Head of Global Safety and Regulatory Sciences and interim Head of R&D, has been promoted to EVP, Head of Development.

The biotech has begin a search for a new EVP, Head of Research. Singhal will serve in this role on an interim basis until the position is filled.
Both executive positions will report to CEO Christopher Viehbacher.
Thursday afternoon, RBC Capital Markets' Brian Abrahams put out a note saying that Eisai (OTCPK:ESALY), Biogen's partner on lecanemab, just activated the patient assistance hotline for the drug. He said this suggests an increased likelihood that approval of lecanemab is imminent.
Read why Seeking Alpha contributor Lane Simonian calls lecanemab "a flawed treatment."